A study for protective mechanisms of VGF, a neurosecretory peptide, in glaucomatous optic nerve degeneration

Research Project

Project/Area Number	26462694
Research Category	Grant-in-Aid for Scientific Research (C)
Allocation Type	Multi-year Fund
Section	一般
Research Field	Ophthalmology
Research Institution	Gifu Pharmaceutical University
Principal Investigator	Shimazawa Masamitsu 岐阜薬科大学, 薬学部, 准教授 (80381721)
Co-Investigator(Kenkyū-buntansha)	原英彰岐阜薬科大学, 薬学部, 教授 (20381717)
Project Period (FY)	2014-04-01 – 2017-03-31
Project Status	Completed (Fiscal Year 2016)
Budget Amount *help	¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000) Fiscal Year 2016: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000) Fiscal Year 2015: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000) Fiscal Year 2014: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Keywords	網膜神経節細胞 / 小胞体ストレス / 緑内障
Outline of Final Research Achievements	In this study, we investigated the involvements of VGF in a mouse experimental glaucoma (optic nerve crush) model. Vgf mRNA increased in retina at the peak of 3 days after optic nerve crush. The VGF protein showed an increase after 7 days after optic nerve crush. Intravitreal administration of VGF peptide (AQEE 30) significantly suppressed retinal ganglion cell death after optic nerve crush. This finding suggests that VGF has a protective effect against retinal ganglion cell disorder.

Report

(4 results)